• linkedin
  • Increase Font
  • Sharebar

    New products: Holmium laser increases stone ablation volume

     

     

     

    Molecular test assesses bladder Ca risk in patients with hematuria

    MDxHealth SA has launched the AssureMDx for Bladder Cancer test in the United States as a laboratory developed test. The noninvasive, urine-based test combines methylation and mutation biomarkers to assess the risk of bladder cancer in patients diagnosed with hematuria. The test has been validated to improve the standard of care by helping to rule out the risk of bladder cancer with a negative predictive value of 99%. Researchers found that the high negative predictive value could help as many as 77% of hematuria patients avoid undergoing a cystoscopy. Additionally, the test’s 93% sensitivity and 85% specificity can help physicians identify patients at an increased risk for bladder cancer who might benefit from cystoscopy. Testing will be performed at the MDxHealth CAP and CLIA-accredited laboratory facilities in Irvine, CA.

    For more information, visit www.mdxhealth.com.

     

    Ben Schwartz
    Ben Schwartz is Associate Editor, Dermatology Times & Urology Times.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results